Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
SinoMab Bioscience Ltd. ( (HK:3681) ) has provided an announcement.
SinoMab BioScience Limited has entered into 26 subscription agreements with independent third-party subscribers to issue a total of 112,810,817 new shares at a price of HK$1.10 each. This move, which does not require shareholder approval, aims to raise approximately HK$124 million in gross proceeds, with net proceeds intended for strategic purposes outlined by the company. The issuance represents about 10.33% of the company’s current share capital and is expected to enhance SinoMab’s financial position and market presence.
More about SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a biotechnology company based in Hong Kong, primarily engaged in the development of therapeutic drugs. The company focuses on the research and development of novel treatments for immunological diseases, leveraging its expertise in monoclonal antibody technology.
Average Trading Volume: 483,968
Technical Sentiment Signal: Hold
Current Market Cap: HK$1.33B
Find detailed analytics on 3681 stock on TipRanks’ Stock Analysis page.